Leuprolide acetate depot and hormonal add-back in endometriosis: A 12- month study

Obstetrics and Gynecology

Volumn 91, Issue 1, 1998, Pages 16-24

  Hornstein, Mark D ^a   Surrey, Eric S ^b   Weisberg, Gerald W ^b   Casino, Leigh A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; LEUPRORELIN; NORETHISTERONE ACETATE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; ENDOMETRIOSIS; FEMALE; HORMONAL REGULATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031973319     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00620-0     Document Type: Article

References (42)

1. 1. Meldrum DR, Chang X, Lu J, Vale W, Rivier J, Judd HL. "Medical oophorectomy" using a long-acting GnRH agonist: A possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982;54:1081-3.
2. 2. Lemay A, Quesnel G. Potential new treatment of endometriosis: Reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 1982;38:376-9.
3. 3. Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 1985;44:583-8.
4. 4. Henzl MR, Corson SL, Moghissi K, Buttram VC, Berqvist C, Jacobson J, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988;318:485-9.
5. 5. Tummon IS, Pepping ME, Binor Z, Radwanska E, Dmowski WP. A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertil Steril 1989;51:390-4.
6. 6. Donnez J, Nisolle-Pochet M, Clerckx-Braun F, Sandow J, Casanas-Roux F. Administration of nasal buserelin as compared with subcutaneous buserelin implant for endometriosis. Fertil Steril 1989;52:27-30.
7. 7. Zorn J-R, Mathieson J, Risquez F, Comaru-Schally AM, Schally AV. Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6-luteinizing hormone-releasing hormone: Long-term follow-up in a series of 50 patients. Fertil Steril 1990;53:401-6.
8. 8. Dlugi AM, Miller JD, Knittle J, Lupron Study Group. Lupron Depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Fertil Steril 1990;54:419-27.
9. 9. Reichel RP, Schweppe K-W, Zoladex Endometriosis Study Group. Goserelin (Zoladex) depot in the treatment of endometriosis. Fertil Steril 1992;57:1197-202.
10. 10. Hornstein MD, Yuzpe AA, Burry KA, Heinrichs LR, Buttram VL Jr, Orwoll ES. Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated with pelvic pain. Fertil Steril 1995;63:955-62.
11. 11. Lemay A, Dewailly DS. Long-term use of the low dose LHRH analogue combined with monthly medroxy-progesterone administration. Horm Res 1989;32 1 Suppl:141-5.
12. 12. Cedars M, Lu K, Meldrum DR, Judd HL. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990;75:641-5.
13. 13. Surrey ES, Gambone JC, Lu JKH, Judd HL. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53:620-6.
14. 14. Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone releasing agonists? J Clin Endocrinol Metab 1990;70: 920-4.
15. 15. Surrey ES, Judd HL. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial. J Clin Endocrinol Metab 1992;72:558-63.
16. 16. Makarainen L, Ronnberg L, Kauppila A. Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 1996;65:29-34.
17. 17. Surrey ES, Fournet N, Voigt B, Judd HL. Effects of sodium etidionate in combination with low-dose norethindrone in patients administered a long-acting gonadotropin releasing hormone agonist: A preliminary report. Obstet Gynecol 1993;81:581-6.
18. 18. Kiilholma P, Tuimala R, Kivinen S, Korhonen M, Hagman E. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 1995;64:903-8.
19. 19. Finkelstein JS, Klibanski A, Schaeffer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994;331:1618-23.
20. 20. American Fertility Society. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril 1985;43:351-2.
21. 21. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness. Am J Obstet Gynecol 1981;139:645-54.
22. 22. Steingold KA, Cedars M, Lu JKH, Randle D, Judd HL, Meldrum DR. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol 1987;69:403-11.
23. 23. Johansen JS, Riis BJ, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988;67: 701-6.
24. 24. Eldred JM, Haynes PJ, Thomas ES. A randomized double-blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol 1992;37:354-9.
25. 25. Howell R, Edmonds D, Dowsett M, Crook D, Lees B, Stevenson J. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: A randomized clinical trial. Fertil Steril 1995;64:474-81.
26. 26. Surrey ES, Voigt B, Fournet N, Judd HL. Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: The role of cyclic sodium etidronate and low-dose norethindrone "add-back" therapy. Fertil Steril 1995;63:747-55.
27. 27. Edgren RA, Sturtevant FM. Potencies of oral contraceptives. Am J Obstet Gynecol 1976;125:1029-38.
28. 28. Barbieri RL. Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992;166:740-5.
29. 29. Englund DE, Johansson EDB. Plasma levels of oestrone, oestradiol, and gonadotrophins in postmenopausal women after oral and vaginal administration of conjugated equine estrogens (Premarin). Br J Obstet Gynaecol 1978;85:957-64.
30. 30. Scialli AR, Jestila KJ, Simon JA. Leuprolide acetate and bone mineral density measured by quantitative digitized radiography. Fertil Steril 1993;59:674-6.
31. 31. Horowitz M, Wishart J, Need AG, Morris H, Philcox J, Nordin C. Treatment of postmenopausal hyperparathyroidism with norethindrone: Effects on biochemistry and forearm mineral density. Arch Intern Med 1987;147:681-5.
32. 32. Horowitz M, Wishart JM, Need AG, Morris HA, Nordin BEC. Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal osteoporosis. Clin Endocrinol 1993;39:649-55.
33. 33. Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 1985;66:789-92.
34. 34. Hutchinson TA, Polansky SM, Feinstein AR. Post-menopausal oestrogens protect against fractures of hip and distal radius. Lancet 1979;2:705-9.
35. 35. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102:319-24.
36. 36. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MI. Oral versus transdermal hormone replacement therapy. Int J Fertil 1993;38 1 Suppl:30-5.
37. 37. Leather AT, Studd JWW, Watson NR, Holland EFN. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet Gynecol 1993;81:104-7.
38. 38. Ravnikar V. Physiology and treatment of hot flushes. Obstet Gynecol 1990;75:3S-8S.
39. 39. Paterson EL. A randomized double-blinded cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynaecol 1982;89:464-72.
40. 40. Miller VT, Barnabei V, Kessler C, Levin G, Smith-Roth A, Griffin M, et al. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women; the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1995;273:199-208.
41. 41. Lindgren R, Berg G, Hammar M, Larsson-Cohn U, Olsson AG. Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol norethindrone acetate. Eur J Obstet Gynecol 1992;47:213-21.
42. 42. Clarkson TB, Shively CA, Morgan TM, Koritnik DR, Adams MR, Kaplan AR. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Obstet Gynecol 1990;75:217-22.